Catalent, Inc. (NYSE:CTLT – Get Rating) – Analysts at Jefferies Financial Group upped their Q2 2023 EPS estimates for shares of Catalent in a report released on Tuesday, January 24th. Jefferies Financial Group analyst D. Windley now expects that the company will earn $0.71 per share for the quarter, up from their previous estimate of $0.70. The consensus estimate for Catalent's current full-year earnings is $2.93 per share. Jefferies Financial Group also issued estimates for Catalent's Q3 2023 earnings at $0.86 EPS.
Get
Catalent alerts:
A number of other equities analysts also recently issued reports on CTLT. TheStreet downgraded shares of Catalent from a "b-" rating to a "c+" rating in a research note on Friday, October 28th. Bank of America cut shares of Catalent from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $125.00 to $60.00 in a report on Wednesday, November 2nd. Argus cut shares of Catalent from a "buy" rating to a "hold" rating in a report on Monday, November 7th. Royal Bank of Canada cut their price objective on shares of Catalent from $125.00 to $73.00 and set an "outperform" rating for the company in a report on Wednesday, November 2nd. Finally, Morgan Stanley cut their price objective on shares of Catalent from $120.00 to $81.00 and set an "overweight" rating for the company in a report on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $92.40.
Catalent Price Performance
Shares of CTLT stock opened at $50.16 on Wednesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.86 and a quick ratio of 2.08. The company has a market capitalization of $9.03 billion, a P/E ratio of 21.44, a P/E/G ratio of 3.63 and a beta of 1.24. The company's 50-day simple moving average is $46.33 and its two-hundred day simple moving average is $71.89. Catalent has a one year low of $40.69 and a one year high of $115.33.
Catalent (NYSE:CTLT – Get Rating) last posted its quarterly earnings data on Tuesday, November 1st. The company reported $0.25 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by ($0.24). The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a return on equity of 12.55% and a net margin of 8.83%.
Insiders Place Their Bets
In other Catalent news, insider Ricky Hopson sold 643 shares of the business's stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $49.36, for a total transaction of $31,738.48. Following the completion of the transaction, the insider now owns 16,452 shares in the company, valued at approximately $812,070.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Manja Boerman sold 780 shares of the business's stock in a transaction on Monday, December 5th. The shares were sold at an average price of $51.70, for a total value of $40,326.00. Following the completion of the sale, the insider now directly owns 15,860 shares of the company's stock, valued at $819,962. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ricky Hopson sold 643 shares of the business's stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $49.36, for a total transaction of $31,738.48. Following the completion of the sale, the insider now directly owns 16,452 shares of the company's stock, valued at $812,070.72. The disclosure for this sale can be found here. Insiders sold 3,874 shares of company stock worth $233,414 in the last 90 days. Corporate insiders own 0.58% of the company's stock.
Institutional Investors Weigh In On Catalent
A number of institutional investors and hedge funds have recently bought and sold shares of CTLT. Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Catalent by 22.5% during the second quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,043 shares of the company's stock worth $326,000 after acquiring an additional 558 shares during the period. US Bancorp DE grew its position in Catalent by 1.4% during the third quarter. US Bancorp DE now owns 19,237 shares of the company's stock worth $1,392,000 after buying an additional 272 shares during the period. Mitsubishi UFJ Trust & Banking Corp grew its position in Catalent by 12.0% during the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 90,954 shares of the company's stock worth $9,759,000 after buying an additional 9,723 shares during the period. Illinois Municipal Retirement Fund grew its position in Catalent by 88.1% during the second quarter. Illinois Municipal Retirement Fund now owns 6,028 shares of the company's stock worth $647,000 after buying an additional 2,824 shares during the period. Finally, Private Advisor Group LLC grew its position in Catalent by 98.5% during the second quarter. Private Advisor Group LLC now owns 5,870 shares of the company's stock worth $630,000 after buying an additional 2,913 shares during the period. 99.38% of the stock is owned by hedge funds and other institutional investors.
Catalent Company Profile
(Get Rating)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Stories
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.
